How long does a molecule actually stick around once it enters circulation? For anyone working with research peptides, the GHK-Cu half-life is one of the first pharmacokinetic questions worth asking — because it shapes how researchers interpret every study the compound appears in. GHK-Cu, the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, is one of the most published-on small peptides in the literature, yet its time course in the body is often misunderstood. This article gathers what published studies actually report about its plasma half-life and pharmacokinetics: the headline number, where that number comes from, why the peptide clears quickly, and what a short half-life does and doesn’t imply for research. Everything here is research framing — no dosing, no usage guidance, no medical advice.
Research-use-only disclaimer: GHK-Cu is not an FDA-approved drug and is not a medicine. It is handled as a research compound for laboratory and scientific investigation only. All products on this site are sold strictly for laboratory research use. This article is educational, contains no dosage information, no administration instructions, and no medical advice.
GHK-Cu Half-Life Facts
Published research puts the GHK-Cu half-life at about 0.5 to 1 hour in plasma. GHK-Cu is a tripeptide of glycine, histidine and lysine, and its small size and plasma enzymes explain the fast clearance. The half-life describes plasma presence, not effect duration. GHK-Cu is supplied as the GLOW Blend with BPC-157 and TB-500, and as the KLOW Blend with KPV, BPC-157 and TB-500. Each vial is lyophilized and carries a lot-specific Certificate of Analysis. GHK-Cu is for laboratory research use only. The GHK-Cu Copper Peptide hub covers the compound, and the GHK-Cu Research Timeline traces the studies behind the numbers.
GHK-Cu Half-Life at a Glance
Before the details, the headline figures researchers cite most often when the GHK-Cu half-life comes up:
~0.5–1 hour
Reported plasma half-life of GHK in Pickart’s peer-reviewed review of the peptide’s literature — the most-quoted GHK-Cu half-life figure in the published record.
200 → 80 ng/mL
Approximate decline in human plasma GHK concentration from age 20 to age 60, reported by Pickart & Margolina — the endogenous baseline this half-life discussion sits on top of.
3 amino acids
GHK is a tripeptide — glycine, histidine, lysine — which partly explains why plasma enzymes clear it fast. Small peptides are short-lived in circulation by nature.
1973
The year Loren Pickart first isolated GHK from human plasma, beginning the five-decade research record behind every modern GHK-Cu half-life claim.
What “Half-Life” Means for a Research Peptide
In pharmacokinetics, half-life is the time it takes for the concentration of a compound in blood plasma to fall by half. It is a measure of presence — how long the intact molecule circulates — not a measure of effect duration. That distinction matters enormously for the GHK-Cu half-life conversation, because the two are frequently conflated in casual discussion.
A short half-life means the compound is cleared from plasma quickly. It does not automatically mean its biological footprint is short. Many compounds trigger downstream changes — gene expression shifts, enzyme induction, tissue remodeling signals — that persist long after the parent molecule is gone. Researchers reading GHK-Cu studies need both numbers in view: the plasma time course and the duration of the measured research endpoints.
Key distinction: The GHK-Cu half-life describes how fast the peptide disappears from plasma. It says nothing, by itself, about how long any downstream research effect lasts. Published GHK-Cu work frequently measures effects over days to weeks, well beyond the plasma residence time.
The 0.5–1 Hour Figure: Where the GHK-Cu Half-Life Number Comes From
The most-cited GHK-Cu half-life figure traces back to a comprehensive peer-reviewed review of GHK research by Loren Pickart, published in 2014, which states that GHK has a half-life of about 0.5 to 1 hour in plasma. This is a literature-synthesis figure rather than a single dedicated human pharmacokinetic trial — and that context is worth understanding.
Why does the number come from a review rather than a clinical PK study? Because GHK-Cu has never been developed as an approved drug, so it never went through the formal Phase 1 pharmacokinetic workup that a drug candidate receives. The 0.5–1 hour figure reflects what the published record — animal studies, in vitro plasma-incubation work, and related peptide research — supports about how fast the tripeptide is broken down in blood. Commercial wellness content often repeats “30 to 60 minutes” as if it were a precise clinical measurement; the honest framing is that it is the best-supported estimate from the published literature.

The same review adds a detail that helps explain the research interest despite the short half-life: rat wound-healing studies found that splitting administration into frequent small exposures over the day dramatically lowered the amount needed compared with single large doses. That observation is consistent with a compound that clears fast — exposure pattern matters more than peak concentration. For researchers, it is a useful reminder that dosing schedules in animal studies are designed around the pharmacokinetics, not independent of them.
Why GHK-Cu Clears So Quickly
A plasma half-life under an hour is not unusual for a tripeptide. Several well-understood mechanisms converge to give the GHK-Cu half-life its short value:
Enzymatic degradation in plasma
Blood plasma is rich in peptidases — enzymes whose job is to cut peptides into smaller fragments. A three-amino-acid chain like GHK presents an easy target: fewer bonds to protect, no folded structure to hide behind. Published discussions of peptide pharmacokinetics consistently identify enzymatic cleavage as the dominant clearance route for short peptides, and GHK is no exception. This is the primary driver of the peptide’s short half-life.
Small molecular size
At around 340 daltons for the free tripeptide (about 402 for the copper complex), GHK-Cu is tiny — well below the threshold where the kidneys filter molecules freely. Small, water-soluble molecules are cleared from circulation far faster than large proteins, which benefit from recycling mechanisms like FcRn-mediated salvage. Size alone predicts a short half-life, even before enzymes get involved.
Copper handling
GHK has an exceptionally high affinity for copper(II) — the published association constant is on the order of 1016, comparable to dedicated copper-transport proteins in plasma. In the body, the peptide readily exchanges copper with albumin and other carriers. Once the complex hands off its copper or is cleaved, the remaining fragments are cleared like any other small peptide debris. The copper chemistry is central to GHK-Cu’s research interest, but it does not grant the molecule any special protection from clearance.
Research takeaway: Nothing about this half-life figure is mysterious. Fast enzymatic breakdown plus small size plus normal renal handling adds up to roughly an hour in plasma. The interesting research question was never “why does it clear fast” — it is “why do its studied effects outlast its presence,” which the next section addresses.

Plasma Presence vs. Research Effects: What the GHK-Cu Half-Life Doesn’t Tell You
The table below separates what half-life measures from what it doesn’t — a distinction that keeps research interpretation honest.
| Question | What the half-life answers | What it doesn’t answer |
|---|---|---|
| How long does intact GHK-Cu circulate? | Yes — roughly 0.5–1 hour in plasma per the published review. | — |
| How long do gene-expression changes last? | — | No — downstream effects are measured separately, often over days. |
| How often did animal studies administer it? | Partially — frequent schedules align with fast clearance. | Study design choices, which vary by research question. |
| Whether effects accumulate with repeated exposure? | — | No — that requires dedicated repeated-exposure studies. |
| How it compares to other small peptides? | Yes — ~1 hour is typical for unmodified short peptides. | — |
The most striking published finding on this front is the gene-expression work: analyses using connectivity-mapping data identified GHK as potentially modulating over 4,000 human genes — roughly a third of the genome in the models studied — with patterns skewed toward repair and anti-inflammatory signaling. Gene expression changes of that kind are not something a molecule needs to be physically present to sustain; once transcription is altered, the cellular program runs on its own timeline. That is the standard pharmacological explanation for how a compound with a sub-hour plasma half-life can be associated with research effects measured over much longer windows.
A Timeline: GHK-Cu’s Journey Through Circulation
Putting the pharmacokinetics in sequence helps make the short half-life intuitive:
Minute 0 — Entry into plasma. Whether endogenous (released during tissue injury, the body’s own GHK-Cu signal) or introduced in a research setting, the intact copper complex enters circulation. Endogenous plasma levels in young adults sit near 200 ng/mL, declining with age.
Minutes 0–30 — Distribution and first-pass cleavage. Plasma peptidases begin cutting the tripeptide. The molecule distributes through the extracellular space; its small size lets it move freely. Copper exchange with albumin and other carriers can occur.
Minutes 30–60 — Half the intact peptide is gone. By roughly the one-hour mark, about half of the original intact GHK has been degraded or cleared, per the published 0.5–1 hour GHK-Cu half-life estimate. Fragments continue through normal small-molecule clearance.
Hours to days — Downstream signaling. The gene-expression and cellular changes attributed to GHK-Cu in published work — collagen-pathway signaling, inflammatory-marker modulation, tissue-remodeling gene programs — play out on their own, longer timescale, independent of the peptide’s continued presence.

GHK vs. GHK-Cu: Does the Copper Change Clearance?
Strictly speaking, most published half-life discussion refers to GHK — the free tripeptide — because the clearance estimates come from studies of the peptide backbone. The copper complex is the form researchers usually work with, since copper binding is considered central to the compound’s studied activity. Does complexation change the half-life?
The published record does not offer a clean head-to-head plasma half-life comparison of GHK versus GHK-Cu. What is established is the chemistry: GHK binds Cu(II) with very high affinity, and in plasma the peptide exists in equilibrium with copper carriers. In practice, researchers treat the copper complex as the relevant species and the 0.5–1 hour figure as the applicable estimate. Anyone designing a study that depends on precise copper-complex pharmacokinetics should note this as a gap rather than assume the free-peptide number transfers exactly.
Honest gap: There is no published dedicated human pharmacokinetic trial establishing a precise GHK-Cu half-life for the copper complex specifically. The 0.5–1 hour figure is the best-supported literature estimate. Treat vendor or forum claims of greater precision with skepticism.
What Researchers Still Don’t Know About GHK-Cu Pharmacokinetics
A responsible half-life overview should close with the open questions, because they shape how the existing data should be read:
- Tissue distribution: Plasma half-life is only one compartment. How the peptide partitions into skin, connective tissue, or other matrices in published models is less characterized.
- Metabolite activity: The fragments left after peptidase cleavage are generally assumed inactive, but the literature does not exhaustively profile them.
- Chronic exposure kinetics: Most data reflect single exposures. How clearance behaves under repeated administration schedules in research models is a thinner evidence base.
- Species differences: The half-life estimate draws heavily on animal and in vitro work; direct human measurements are limited.
None of these gaps invalidate the published estimate — they simply mark where the research frontier sits. For a compound studied since 1973, the pharmacokinetic picture is unusually shaped: deep mechanistic and gene-expression literature on one side, and a pharmacokinetic profile assembled from reviews and inference rather than dedicated trials on the other.
For the wider research context, the GHK-Cu Research Timeline traces the studies behind the half-life figure, from the 1973 isolation to the gene-expression era, and the GHK-Cu Copper Peptide hub covers the compound from the start. GHK-Cu is supplied as the GLOW Blend and the KLOW Blend, each with a lot-specific Certificate of Analysis, for laboratory research use only.
GHK-Cu Half-Life: Key Takeaways for Researchers
- The best-supported GHK-Cu half-life figure from the published literature is about 0.5–1 hour in plasma (Pickart’s peer-reviewed review).
- Fast clearance is expected: small size plus abundant plasma peptidases make sub-hour half-lives normal for unmodified tripeptides.
- Half-life measures plasma presence, not effect duration — published gene-expression and tissue-remodeling findings are measured over much longer windows.
- No dedicated human PK trial pins down a more precise number; treat hyper-precise vendor claims accordingly.
- Frequent administration schedules in animal studies are consistent with — and designed around — the short GHK-Cu half-life.
Research framing only — not a recommendation for any use. GHK-Cu is supplied as the GLOW Blend and the KLOW Blend, each with a lot-specific Certificate of Analysis, for laboratory research use only.
GHK-Cu Half-Life: Frequently Asked Questions
Direct answers to the questions researchers ask most about GHK-Cu pharmacokinetics.
What is the half-life of GHK-Cu?
The most-cited published figure puts the GHK-Cu half-life at about 0.5 to 1 hour in plasma, from Loren Pickart’s peer-reviewed review of the GHK literature. This is a literature-synthesis estimate rather than a result from a dedicated human pharmacokinetic trial, since GHK-Cu has never been developed as an approved drug.
Why is the GHK-Cu half-life so short?
Three converging reasons: GHK is a tiny tripeptide that plasma peptidases cleave quickly; its small molecular size allows rapid renal clearance; and it lacks the structural protections (folding, recycling mechanisms) that give large proteins longer circulation times. A sub-hour GHK-Cu half-life is typical for unmodified short peptides.
Does a short GHK-Cu half-life mean its effects are short-lived?
Not necessarily. The GHK-Cu half-life measures how long the intact molecule circulates, not how long downstream changes last. Published GHK-Cu research reports gene-expression modulation and tissue-remodeling findings measured over days to weeks — effects that play out on a cellular timescale independent of the peptide’s plasma residence.
Is the half-life of GHK the same as GHK-Cu?
The published 0.5–1 hour figure technically refers to GHK, the free tripeptide. GHK-Cu is the copper complex researchers usually work with. The literature does not provide a clean head-to-head comparison, so researchers generally apply the same estimate while noting the gap.
How do researchers account for the short GHK-Cu half-life in study design?
Published animal work has explored frequent, repeated administration schedules rather than single large exposures — a design choice consistent with fast clearance. The specific schedules are study-design decisions documented in the primary literature, not guidance provided here.
Where can I read the primary GHK-Cu research?
Start with the peer-reviewed reviews: Pickart & Margolina’s 2018 review in the International Journal of Molecular Sciences, indexed on PubMed, and the Wikipedia overview of copper peptide GHK-Cu for background. General peptide background is covered in the peptide article, and approval-status questions are answered by the FDA’s drug information pages.
GHK-Cu Half-Life: Final Research Notes
The GHK-Cu half-life story is refreshingly straightforward once the layers are separated: about half an hour to an hour in plasma, per the best published estimate; cleared fast for entirely ordinary biochemical reasons; and no contradiction between that short presence and the longer-timescale findings that make the compound interesting to researchers. The confusion around the number comes mostly from treating a literature-synthesis estimate as a clinical measurement — and from conflating presence with effect.
Kept in that frame, this half-life figure is less a limitation than a design parameter: it explains the administration patterns used in published animal work, it sets expectations for how exposure relates to measured endpoints, and it reminds researchers that for signaling peptides, the message routinely outlives the messenger.

